Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.

"Conflict of interest: CM-Q, ML-L, JD-D, and AO-S have attended several congresses, whose registration, travel, and accommodation costs covered by MSD, GSK, AZ, and Sanofi Pasteur (SP) AO-S and JD-D, along with their institution, have received research grants from SP and GSK related to respiratory syncytial virus preventive strategies. AO-S and JD-D have acted as advisors for this immunisation strategy to SP, with AO-S also advising Moderna. AM-I has received fees for conferences/experts’ meetings from SP and for educational events from MSD. FXL-L received grants from the Foundation for Influenza Epidemiology (France), payments to his institution from SP and from CIBERESP (Instituto de Salud Carlos III), and individual payments for advisory boards from SP. FXL-L also holds a leadership role in the European Society of Clinical Virology as an Executive Member."

"Funding statement This work is, in part, funded by the Instituto de Salud Carlos III from the European funds of the Recovery, Transformation and Resilience Plan, with file code CD22/00122, by virtue of the Resolution of the Directorate of the Instituto de Salud Carlos III, O.A., M.P. of 14 December 2022, awarding the Sara Borrell Contracts of the 2022 call of the Strategic Action in Health 2021-2023. This work is also funded by the European Union - NextGenerationEU."